Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586102 | 0.83 | NPC1 (0.51) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL9630011 | 0.83 | RAB9A (0.50) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL28924859 | 0.82 | MEN1 (0.55) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL14941820 | 0.80 | RAB9A (0.43) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL9628662 | 0.79 | POLB (0.56) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL5888794 | 0.79 | NPC1 (0.61) | RAB9ANPC1CYP2D6CYP2C19MEN1 | |
| SCHEMBL31489988 | 0.79 | RAB9A (0.47) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL16436772 | 0.79 | MEN1 (0.60) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL170196 | 0.79 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL29374931 | 0.79 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | RAB9A 1896/4885NPC1 2028/4885AR 4099/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAB9A 763/4885NPC1 1992/4885AR 4185/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | RAB9A 1071/4885NPC1 1932/4885AR 4382/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885AR 3328/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAB9A 812/4885NPC1 2214/4885AR 4323/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | RAB9A 2823/4885NPC1 2458/4885AR 1264/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885AR 3328/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | RAB9A 3039/4885NPC1 469/4885AR 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.